Bullish Reversal
Bullish reversal indicators.
Increasing volume with solid support, as GALT enters 2021 catalysts.
GALT
Due Diligence Cliff's Notes:
— Leading inhibitor under development for Galectin-3, key native immune system protein involved in numerous inflammatory and fibrotic diseases and various cancers.
— The only drug that has ever shown any clinically meaningful (not just lab biomarker) benefit for NASH (prevention of varices), testing to repeat these results in the NASH-RX trial.
— Appears to reduce the side effects of cancer immunotherapy in the MRK Keytruda combo trial. Next readout in Q2.
— Upcoming hepatic impairment (HI) biomarker results will guide the potential launch to additional indications.
— Chairman and largest shareholder is the multi-billionaire founder/owner of ULINE. It’s his passion. His long time exec is now the GALT CEO and he has a board member from his family wealth office.
— GALT CEO is taking 80% of his pay in the form of stock.
— HC Wainwright $12 price target.
— Multiple shots on goal include multiple indications + combo therapy possibility for each indication (drug has excellent safety profile).
— BMY stated in a patent filed last year that the Gal3 inhibitor is proven to work for cancer immunotherapy. So we know that BMY is knowledgeable/ has their eyes on this.
— Finished converting all preferred shares to common shares last year (historically, this is typically done for buy-in or buyout scenarios).
Increasing volume with solid support, as GALT enters 2021 catalysts.
GALTDue Diligence Cliff's Notes:
— Leading inhibitor under development for Galectin-3, key native immune system protein involved in numerous inflammatory and fibrotic diseases and various cancers.
— The only drug that has ever shown any clinically meaningful (not just lab biomarker) benefit for NASH (prevention of varices), testing to repeat these results in the NASH-RX trial.
— Appears to reduce the side effects of cancer immunotherapy in the MRK Keytruda combo trial. Next readout in Q2.
— Upcoming hepatic impairment (HI) biomarker results will guide the potential launch to additional indications.
— Chairman and largest shareholder is the multi-billionaire founder/owner of ULINE. It’s his passion. His long time exec is now the GALT CEO and he has a board member from his family wealth office.
— GALT CEO is taking 80% of his pay in the form of stock.
— HC Wainwright $12 price target.
— Multiple shots on goal include multiple indications + combo therapy possibility for each indication (drug has excellent safety profile).
— BMY stated in a patent filed last year that the Gal3 inhibitor is proven to work for cancer immunotherapy. So we know that BMY is knowledgeable/ has their eyes on this.
— Finished converting all preferred shares to common shares last year (historically, this is typically done for buy-in or buyout scenarios).
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.